Drug intelligence / Profile preview

ADR-002K

Development stage: Phase 2
Lead developer: Rohto Pharmaceutical
Modality: Stem Cell Therapies → Cell Therapies
Administration: Epicardial

Overview

ADR-002K is an allogeneic adipose-derived mesenchymal stem cell (ADSC) therapy developed by Rohto Pharmaceutical. It is currently in clinical development for the treatment of heart failure in patients with ischemic heart disease who are undergoing coronary artery bypass grafting (CABG). The therapy leverages the regenerative, anti-inflammatory, and pro-angiogenic properties of mesenchymal stem cells to promote myocardial repair and improve cardiac function following surgical revascularization. By delivering these cells directly or adjacently to the damaged heart tissue, the treatment aims to stimulate the repair of ischemic myocardium through paracrine signaling and potential cellular differentiation.

Other names: allogeneic adipose-derived mesenchymal stem cellsADSC

Beyond the preview

Go deeper on ADR-002K.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADR-002K.

Explore the full profile